Quinoline derivatives as inhibitors of MEK enzymes

US6809106B1 · kind B1 · utility

Assignee

• ASTRAZENECA AB · SE

Inventor

• Keith Gibson · Macclesfield, GB

Key dates

• Filing date: Oct 17, 2001
• Grant date: Oct 26, 2004
• Expiry date: Oct 17, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D215/48
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound of formula (I) or a pharmaceutically acceptable salt thereof; for use as a medicament wherein:n is 0-1;Y is selected from —NH—, —O—, —S—, or —NR7— where R7 is alkyl of 1-6 carbon atomsR5 is chloro or bromo;Y is selected from —NH—, —O—, —S—, or —NR7— where R7 is alkyl of 1-6 carbon atomsR6 is a specified cyclic group which may be substituted by various specified substituents,or R6 is a group —R8—X—R9 whereR8 is selected from various cycloalkyl, pyridinyl, pyimidinyl, or phenyl ring; any of which may be optionally subsituted as described,where X is selected from CH2, —NH—, —O—, —S—, CH2 or —NR5— where R5 is alkyl of 1-6 carbon atoms, and R9 is a group (CH2)mR10 where m is 0, or an integer of from 1-3 and R10 is an optionally substituted aryl or optionally substituted cycloalkyl ring of up to 10 carbon atoms,or R10 is a heterocyclic ring containing 1 or 2 oxygen atoms and optionally one or more substitutents; and R1, R2, R3 and R4 are each independently selected from hydrogen or various specified organic groups. No…